GLP-1, ADHD medication costs leading surge in drug insurance claims: report
Overall drug costs in Canada rose 9.5 per cent in 2025 compared to 2024, a new report by private insurance company GreenShield said.
Drug insurance claims across Canada have seen a significant surge in 2025, with a 9.5% increase in costs according to a report by GreenShield insurance company. The rise is largely attributed to the growing demand for treatments related to diabetes, obesity, and other chronic conditions. GLP-1 medications, such as semaglutide, have seen a significant rise in costs, with a 47.7% increase compared to 2024.
Semaglutide accounted for 6.6% of total drug insurance costs in Canada in 2025 and was the top product by total drug cost. The average claimant spent $2,489 on drugs like Ozempic, Rybelsus, and Wegovy for diabetes and weight management. The report also noted a significant rise in ADHD medication costs, particularly for methylphenidate and lisdexamfetamine, with a 23.1% increase in claims among people aged 35-44.
Brief written by urgent.news from Global News's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
